Version 1
: Received: 20 October 2018 / Approved: 22 October 2018 / Online: 22 October 2018 (10:45:08 CEST)
How to cite:
Yang, Y.; Lu, M.; Zou, Q.; Liu, X.; Hwang, E. Antidiabetic and Renoprotective Effects of Acankoreagenin from the Leaves of Acanthopanax Gracilistylus in Streptozotocin-Induced Type I Diabetic Rats. Preprints2018, 2018100489. https://doi.org/10.20944/preprints201810.0489.v1
Yang, Y.; Lu, M.; Zou, Q.; Liu, X.; Hwang, E. Antidiabetic and Renoprotective Effects of Acankoreagenin from the Leaves of Acanthopanax Gracilistylus in Streptozotocin-Induced Type I Diabetic Rats. Preprints 2018, 2018100489. https://doi.org/10.20944/preprints201810.0489.v1
Yang, Y.; Lu, M.; Zou, Q.; Liu, X.; Hwang, E. Antidiabetic and Renoprotective Effects of Acankoreagenin from the Leaves of Acanthopanax Gracilistylus in Streptozotocin-Induced Type I Diabetic Rats. Preprints2018, 2018100489. https://doi.org/10.20944/preprints201810.0489.v1
APA Style
Yang, Y., Lu, M., Zou, Q., Liu, X., & Hwang, E. (2018). Antidiabetic and Renoprotective Effects of Acankoreagenin from the Leaves of <em>Acanthopanax Gracilistylus</em> in Streptozotocin-Induced Type I Diabetic Rats. Preprints. https://doi.org/10.20944/preprints201810.0489.v1
Chicago/Turabian Style
Yang, Y., Xiang-Qian Liu and Eun-Hee Hwang. 2018 "Antidiabetic and Renoprotective Effects of Acankoreagenin from the Leaves of <em>Acanthopanax Gracilistylus</em> in Streptozotocin-Induced Type I Diabetic Rats" Preprints. https://doi.org/10.20944/preprints201810.0489.v1
Abstract
This present study was designed to find out whether the acankoreagenin showed the antidiabetic and renoprotective effects in streptozotocin (STZ)-induced diabetic nephropathy (DN) rats. Type I diabetes was induced by a single intraperitoneal injection of STZ (70 mg/kg). At the end of the experiment, rats were euthanized and serum/plasma was separated for the determination of glucose, insulin, glycated hemoglobin A1c (HbA1c), C-peptide, biochemical parameters, and kidney function. One kidney was used for determining glutathione, superoxide dismutas, malondialdehyde, and tumor necrosis factor-alpha levels. The other kidney and pancreas were used for histopathological studies and immunohistochemical measurement of transforming growth factor beta (TGF-β) or NF-κB. Acankoreagenin (2 mg/kg) treatments led to a significant reduction in blood glucose assessed via oral glucose tolerance test (OGTT) in diabetic rats at 2 h. The treatment also resulted in improved body weight, decreased HbA1c, restored lipid profile, and renal oxidative stress. By inhibiting NF-κB, the release of proinflammatory cytokines was suppressed and by inhibiting TGF-β, the renal fibrosis was suppressed in STZ-induced diabetic rat model. Histopathological injury was also observed in pancreatic and renal tissues. These findings support the beneficial effect of acankoreagenin treatment in DN, which could be attributed to its antidiabetic and renoprotective effects.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
